Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial

Nephrology

Volumn 21, Issue 4, 2016, Pages 295-300

  Shema Didi, Lilach ^a   Kristal, Batya ^a,b   Eizenberg, Sarit ^a   Marzuq, Nabil ^a   Sussan, Majdy ^a   Feldman Idov, Yulie ^a   Ofir, Pnina ^a   Atar, Shaul ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

acute kidney injury; angiography; chronic kidney disease; contrast media; erythropoietin

Indexed keywords

ACETYLCYSTEINE; CREATININE; CYSTATIN C; IODIXANOL; IOPROMIDE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE; BIOLOGICAL MARKER; CONTRAST MEDIUM; CST3 PROTEIN, HUMAN; ERYTHROPOIETIN; IODOBENZOIC ACID DERIVATIVE; IOHEXOL; LCN2 PROTEIN, HUMAN; PROTECTIVE AGENT; RECOMBINANT PROTEIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SENSITIVITY ANALYSIS; ACUTE KIDNEY FAILURE; ANALOGS AND DERIVATIVES; BLOOD; CELL PROTECTION; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; CORONARY ANGIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISRAEL; MIDDLE AGED; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; URINE; VERY ELDERLY;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; BIOMARKERS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CYSTATIN C; CYTOPROTECTION; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IOHEXOL; ISRAEL; LIPOCALIN-2; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIIODOBENZOIC ACIDS;

EID: 84962142246     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12609     Document Type: Article

References (36)

1. Katzberg RW,. Contrast medium-induced nephrotoxicity: which pathway? Radiology 2005; 235: 752-5.
2. Mehran R, Nikolsky E,. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. Suppl. 2006: S11-15.
3. Maeder M, Klein M, Fehr T, Rickli H,. Contrast nephropathy: review focusing on prevention. J. Am. Coll. Cardiol. 2004; 44: 1763-71.
4. Lasser EC, Lyon SG, Berry CC,. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997; 203: 605-10.
5. Shema L, Ore L, Geron R, Kristal B,. Contrast-induced nephropathy among Israeli hospitalized patients: incidence, risk factors, length of stay and mortality. Isr. Med. Assoc. J. 2009; 11: 460-4.
6. McCullough PA, Sandberg KR,. Epidemiology of contrast-induced nephropathy. Rev. Cardiovasc. Med. 2003; 4 (Suppl 5): S3-9.
7. Hassan K, Simri W, Rubenchik I, et al., Effect of erythropoietin therapy on polyneuropathy in predialytic patients. J. Nephrol. 2003; 16: 121-5.
8. Sanaei-Ardekani M, Movahed MR, Movafagh S, Ghahramani N,. Contrast-induced nephropathy: a review. Cardiovasc. Revasc. Med. 2005; 6: 82-8.
9. Kristal B, Shurtz-Swirski R, Tanhilevski O, et al., Epoetin-alpha: preserving kidney function via attenuation of polymorphonuclear leukocyte priming. Isr. Med. Assoc. J. 2008; 10: 266-72.
10. Kristal B, Shurtz-Swirski R, Shasha SM, et al., Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Nephron 1999; 81: 406-13.
11. Sela S, Shurtz-Swirski R, Sharon R, et al., The polymorphonuclear leukocyte-a new target for erythropoietin. Nephron 2001; 88: 205-10.
12. Shurtz-Swirski R, Kristal B, Shasha SM, Shapiro G, Geron R, Sela S,. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in continuous ambulatory dialysis patients. Nephron 2002; 91: 759-61.
13. Shurtz-Swirski R, Kristal B, Shkolnik T, Weissman I, Shapiro G, Shasha SM,. Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients. Nephron 1996; 72: 27-9.
14. Chatterjee PK,. Pleiotropic renal actions of erythropoietin. Lancet 2005; 365: 1890-2.
15. Lund A, Lundby C, Olsen NV,. High-dose erythropoietin for tissue protection. Eur. J. Clin. Invest. 2014; 44: 1230-8.
16. Paraskevas KI, Giannoukas AD, Mikhailidis DP,. Statins and contrast-induced nephropathy: issues requiring further investigation. Int. J. Cardiol. 2011; 151: 364.
17. Quintavalle C, Fiore D, De Micco F, et al., Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012; 126: 3008-16.
18. Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C,. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am. J. Cardiol. 2014; 114: 541-8.
19. Aluclu MU, Acar A, Guzel A, Bahceci S, Yaldiz M,. Evaluation of erythropoietin effects on cerebral ischemia in rats. Neuro Endocrinol. Lett. 2007; 28: 170-4.
20. Bahlmann FH, Fliser D,. Erythropoietin and renoprotection. Curr. Opin. Nephrol. Hypertens. 2009; 18: 15-20.
21. Calvillo L, Latini R, Kajstura J, et al., Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 4802-6.
22. Ehrenreich H, Hasselblatt M, Dembowski C, et al., Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 2002; 8: 495-505.
23. Goldfarb M, Rosenberger C, Ahuva S, Rosen S, Heyman SN,. A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats. Ren. Fail. 2006; 28: 345-50.
24. Gong H, Wang W, Kwon TH, et al., EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004; 66: 683-95.
25. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M,. Antioxidative effects of erythropoietin. Kidney Int. Suppl. 2007: S10-15.
26. Patel NS, Sharples EJ, Cuzzocrea S, et al., Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004; 66: 983-9.
27. Spandou E, Tsouchnikas I, Karkavelas G, et al., Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol. Dial. Transplant. 2006; 21: 330-6.
28. Yang CW, Li C, Jung JY, Shin SJ, et al., Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003; 17: 1754-5.
29. Bahlmann FH, De Groot K, Spandau JM, et al., Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-6.
30. Santhanam AV, d'Uscio LV, Peterson TE, Katusic ZS,. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 2008; 29: 1451-5.
31. Lipsic E, van der Meer P, Henning RH, et al., Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 2004; 44: 473-9.
32. Bellomo R, Kellum JA, Ronco C,. Defining acute renal failure: physiological principles. Intensive Care Med. 2004; 30: 33-7.
33. Honore PM, Joannes-Boyau O, Boer W,. The early biomarker of acute kidney injury: in search of the Holy Grail. Intensive Care Med. 2007; 33: 1866-8.
34. Mishra J, Ma Q, Prada A, et al., Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003; 14: 2534-43.
35. Delanaye P, Lambermont B, Chapelle JP, Gielen J, Gerard P, Rorive G,. Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Med. 2004; 30: 980-3.
36. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S,. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol. Dial. Transplant. 2007; 22: 295-6.